FDA advisors unanimously vote to approve Moderna’s mRNA after agency drama

FDA advisory committee members unanimously voted 9-0 to recommend approval of Moderna’s mRNA-based seasonal flu vaccine, marking a significant turnaround after earlier agency resistance and controversy.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviewed data on Moderna’s vaccine, known as mRNA-1010 or branded as mFlusiva, during an all-day session. The panel’s support follows a review of Phase 3 clinical trial data involving over 40,000 adults aged 50 and older, which indicated the vaccine was approximately 27% more effective than standard flu vaccines. Additionally, a smaller trial with nearly 3,000 participants aged 65 and older showed the vaccine elicited stronger immune responses than high-dose flu vaccines, which are typically recommended for this age group.

FDA scientists presented the data, supporting the vaccine’s efficacy and safety profile, which was generally well-received by the committee. Notably, experts highlighted the potential of the mRNA platform for rapid vaccine development and improved responsiveness to emerging strains, emphasizing its role in future pandemic preparedness.

This positive recommendation contrasts sharply with earlier conflicts within the FDA, notably a February decision by a Trump-era official, Vinay Prasad, who refused to review Moderna’s application, citing concerns over trial adequacy. The FDA later reversed that decision after widespread criticism, and Prasad was eventually removed from his position amid other controversies, including the rejection of a gene therapy for Huntington’s disease.

Why the FDA Advisory Vote Matters for Flu Vaccines

The committee’s unanimous support is a critical step toward FDA approval, which could lead to the vaccine’s release later this year. If approved, the vaccine would provide an updated, potentially more effective flu prevention option, especially for older adults. This development also signals a possible shift in the FDA’s stance on mRNA vaccines beyond COVID-19, highlighting their versatility and potential for broader infectious disease applications. The approval process now hinges on the FDA’s final decision, expected by August 5, and subsequent CDC recommendations, which are essential for widespread adoption and coverage.

However, ongoing political and legal challenges, particularly concerning the CDC’s advisory committee, may influence the vaccine’s ultimate deployment. The outcome will impact public health strategies for flu season and future pandemic preparedness, making this a pivotal moment in vaccine development and regulation.

Background of FDA’s Vaccine Review Controversies

In February, a controversy erupted when Vinay Prasad, a Trump-appointed official at the FDA, refused to review Moderna’s flu vaccine application, claiming the trial data was not adequate. This decision was widely criticized and was reversed within a week after public and scientific outcry. Prasad’s actions reflected broader tensions within the FDA during that period, which included rejection of other innovative therapies and contentious decisions on vaccine evaluation. Prasad was eventually removed from his position in April amid multiple controversies, including his rejection of a gene therapy for Huntington’s disease, which was later approved after the reversal of his decision.

The current review and vote mark a significant departure from that episode, indicating a possible return to more conventional scientific evaluation processes at the FDA. The approval process for this vaccine now proceeds with the agency’s scheduled deadline of August 5, aiming for a potential rollout later this year.

“The studies presented were very well conducted and robust in demonstrating efficacy.”

— an anonymous researcher

Remaining Questions About Final Approval and Distribution

It remains unclear whether the FDA will approve Moderna’s vaccine by the August 5 deadline. Additionally, the impact of ongoing legal challenges to CDC advisory committees, particularly the injunction affecting the ACIP, could influence the vaccine’s recommendation for widespread use. The timeline for final approval and distribution is still uncertain, pending regulatory and legal developments.

Next Steps for Moderna’s mRNA Flu Vaccine Approval and Deployment

The FDA is expected to make a final decision on approval by August 5. If approved, Moderna plans to release the vaccine later this year, pending CDC’s recommendation. The CDC’s advisory committee, the ACIP, must also review and endorse the vaccine for it to be broadly recommended and covered by insurance. However, legal challenges to the CDC’s advisory process may delay or complicate this step. The next few weeks will determine whether the vaccine becomes available for the upcoming flu season and how quickly it will be integrated into public health strategies.

Key Questions

What does the FDA advisory committee’s vote mean for Moderna’s flu vaccine?

The 9-0 vote indicates strong scientific support for the vaccine’s efficacy and safety, moving it closer to final FDA approval and potential market availability.

When will the FDA decide on Moderna’s vaccine?

The FDA has set a deadline of August 5 to make its decision regarding approval.

What are the next steps after FDA approval?

If approved, the vaccine will be reviewed by the CDC’s advisory committee, which will recommend its use. Legal and political challenges could influence this process.

Why was there controversy over the vaccine review earlier this year?

A Trump-appointed official refused to review Moderna’s application, claiming the trial data was inadequate, leading to widespread criticism and eventual reversal of the decision.

How might legal issues affect the vaccine’s rollout?

Legal challenges to CDC advisory committees, such as injunctions, could delay or limit the vaccine’s recommendation and distribution, impacting its availability for the upcoming flu season.

Source: Hacker News